{"id":251878,"date":"2026-02-24T00:00:00","date_gmt":"2026-02-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0064-biopharma-atopic-dermatitis-atopic-eczema-epidemiology\/"},"modified":"2026-08-20T11:21:24","modified_gmt":"2026-08-20T11:21:24","slug":"epidim0064-biopharma-atopic-dermatitis-atopic-eczema-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0064-biopharma-atopic-dermatitis-atopic-eczema-epidemiology-emerging-markets\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of atopic dermatitis\/atopic eczema (AD) includes\u00a0epidemiological estimates of key patient populations across 45 countries worldwide. We report the total prevalence of <abbr title=\"atopic dermatitis\">AD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"atopic dermatitis\">AD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"atopic dermatitis\">AD<\/abbr>, how many in each country across the developed world and China have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"atopic dermatitis\">AD<\/abbr>, how many in each country across the developed world and China are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"atopic dermatitis\">AD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided to ensure full transparency in our research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts 13\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr>.<\/li>\n<li>Total 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr> by severity.<\/li>\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr> by severity.<\/li>\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr> by treatment status.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251878","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}